Market capitalization | $22.15m |
Enterprise Value | $30.83m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 90.68 |
P/S ratio (TTM) P/S ratio | 65.15 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -47.71% |
Revenue (TTM) Revenue | $340.00k |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
5 Analysts have issued a Clene Inc forecast:
5 Analysts have issued a Clene Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 0.34 0.34 |
48%
48%
|
|
Gross Profit | -1.37 -1.37 |
8%
8%
|
|
EBITDA | -31 -31 |
18%
18%
|
EBIT (Operating Income) EBIT | -33 -33 |
18%
18%
|
Net Profit | -39 -39 |
20%
20%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.
Head office | United States |
CEO | Robert Etherington |
Employees | 76 |
Founded | 2013 |
Website | www.clene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.